WO2024079623 - TRICYCLIC COMPOUNDS AND THEIR USES

National phase entry:
Publication Number WO/2024/079623
Publication Date 18.04.2024
International Application No. PCT/IB2023/060166
International Filing Date 10.10.2023
Title [English] TRICYCLIC COMPOUNDS AND THEIR USES [French] COMPOSÉS TRICYCLIQUES ET LEURS UTILISATIONS
Applicants ** NOVARTIS AG Lichtstrasse 35 4056 Basel, CH
Inventors ** BORDAS, Vincent c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH FUREGATI, Markus c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH HAMON, Jacques c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH HINRICHS, Juergen Hans-Hermann c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH HONG, Ziyue China Novartis Inst for Biomedical Research Co Ltd., 4218 Jinke Road Pudong New Area, Shanghai 201203, CN LIMA, Fabio c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH LIMAM, Fatma c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH MOEBITZ, Henrik c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH NOCITO, Sandro c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH SCHMIEDEBERG, Niko c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH SCHOEPFER, Joseph c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH STRANG, Ross c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel, CH ZECRI, Frederic c/o Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139, US YU, Huangchao Suzhou Novartis Technical Development Co., Ltd., #18-1, Tonglian Road, Bixi Subdistrict Changshu, Jiangsu 215537, CN ZHANG, Yong Suzhou Novartis Technical Development Co., Ltd., #18-1, Tonglian Road, Bixi Subdistrict Changshu, Jiangsu 215537, CN YANG, Xinkan Suzhou Novartis Technical Development Co., Ltd., #18-1, Tonglian Road, Bixi Subdistrict Changshu, Jiangsu 215537, CN ZHANG, Sisi Suzhou Novartis Technical Development Co., Ltd., #18-1, Tonglian Road, Bixi Subdistrict Changshu, Jiangsu 215537, CN LI, Wei Suzhou Novartis Technical Development Co., Ltd., #18-1, Tonglian Road, Bixi Subdistrict Changshu, Jiangsu 215537, CN
Priority Data PCT/CN2022/124865  12.10.2022  CN 22208192.9  17.11.2022  EP 63/494,033  04.04.2023  US PCT/CN2023/108913  24.07.2023  CN
front page image
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 5991
EPO Filing, Examination 39585
Japan Filing 564
South Korea Filing 679
USA Filing, Examination 22185
+ Add country
MasterCard Visa
Total: 69004
The term for entry into the National Phase has expired. This quotation is for informational purposes only.

QUOTE TO EMAIL ONLINE QUOTE
Abstract [English] , y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention. [French] , y, R, M, W, L, V, T, Y, J, K et A sont tels que décrits dans la description, des utilisations thérapeutiques desdits composés, des utilisations desdits composés en tant que produits chimiques de recherche, une composition pharmaceutique et des combinaisons comprenant lesdits composés, et des procédés de fabrication des composés de l'invention.